If so, consider joining the PRIOH-1 study, a herpes simplex virus (HSV-1 and HSV-2) clinical trial investigating a potential new treatment for people who are immunocompromised with HSV skin lesions that have failed to heal or show any improvement with acyclovir treatment. What we learn from the PRIOH-1 study could potentially help those who are immunocompromised and suffering from acyclovir-resistant mucocutaneous HSV infections in the future.
